Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.60 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287495 | 0.88 | CYP2C9 (0.60) | SLC22A12CYP2C9EYA3CNR2CYP2C19 | |
| SCHEMBL1287561 | 0.86 | CYP2C9 (0.59) | SLC22A12CYP2C9EYA3CNR2CYP2C19 | |
| SCHEMBL1287462 | 0.81 | CYP2C9 (0.83) | SLC22A12CYP2C9EYA3CYP2C19L3MBTL1 | |
| SCHEMBL11749225 | 0.78 | THRB (0.47) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL22072514 | 0.77 | SLC22A12 (0.61) | SLC22A12CYP2C9EYA3CNR2CYP2C19 | |
| SCHEMBL1287630 | 0.76 | SLC22A12 (1.00) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287565 | 0.75 | SLC22A12 (0.88) | SLC22A12CYP2C9EYA3CNR2CYP2C19 | |
| SCHEMBL1287600 | 0.75 | SLC22A12 (0.88) | SLC22A12CYP2C9EYA3CYP2C19L3MBTL1 | |
| SCHEMBL1287500 | 0.75 | SLC22A12 (0.86) | SLC22A12CYP2C9EYA3CYP2C19NPC1 | |
| SCHEMBL1287515 | 0.75 | SLC22A12 (0.86) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885CYP2C9 203/4885EYA3 4828/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885CYP2C9 203/4885EYA3 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.